AI Terminal
Pharmanutra
Business and Financial Review • Apr 9, 2025
4324_rns_2025-04-09_a8a268d4-d999-4760-a673-6963560fb290.pdf
Business and Financial Review
Open in ViewerOpens in native device viewer
| Informazione Regolamentata n. 20106-21-2025 |
Data/Ora Inizio Diffusione 9 Aprile 2025 08:00:12 |
Euronext Star Milan | |
|---|---|---|---|
| Societa' | : | PHARMANUTRA | |
| Identificativo Informazione Regolamentata |
: | 203860 | |
| Utenza - Referente | : | PHARMANUTRAN04 - Roberto Lacorte | |
| Tipologia | : | REGEM | |
| Data/Ora Ricezione | : | 9 Aprile 2025 08:00:12 | |
| Data/Ora Inizio Diffusione | : | 9 Aprile 2025 08:00:12 | |
| Oggetto | : | Pharmanutra: THE INTERNATIONALISATION PROCESS CONTINUES |
|
| Testo del comunicato |
Vedi allegato
PHARMANUTRA S.P.A.: THE INTERNATIONALISATION PROCESS CONTINUES
THE COMPANY SIGNS THREE NEW AGREEMENTS FOR THE DISTRIBUTION OF ITS PRODUCTS ABROAD. FROM THIS YEAR ONWARDS, IT WILL ALSO BE PRESENT IN MOROCCO, PERU AND BAHRAIN
Pisa, 9 April 2025 –PharmaNutra S.p.A. (MTA; Ticker PHN), a company specialised in mineral-based nutritional supplements and medical devices for muscles and joints, announces three new agreements for the distribution of its products abroad. The countries involved are Morocco, Bahrain and Peru, thus joining the 85 countries in which the company, founded in 2003 by brothers Andrea and Roberto Lacorte, is already present.
The agreement for distribution in Morocco was signed last September with Alcantara Pharmaceuticals, and registration is now underway for the first products - SiderAL®, SiderAL® Drops and Apportal® - which will be marketed from next year in what is actually one of Africa's leading economies.
On the other hand, the agreement for distribution in Peru was signed last December with partner Lukoll, an industry-leading company with a strong presence throughout South America. The agreement, in this first phase, foresees the distribution in Peru of two products of the SiderAL® line - SiderAL® Forte Oro and SiderAL® Drops - paediatrics oral iron food supplements manufactured on the basis of the innovative Sucrosomial® Technology, a PharmaNutra S.p.A.'s patent that continues to gain important recognition from the scientific community.
The Kingdom of Bahrain, comprising more than 30 islands in the Persian Gulf with high economic potential, is the latest country to be added to the long list of countries in which PharmaNutra S.p.A. successfully operates. The agreement in question was reached with partner Bio Ceutics, which for the moment will distribute three products from the SiderAL® line: SiderAL® Forte, SiderAL® Drops and SiderAL® Folic.
Carlo Volpi, Managing Director of PharmaNutra S.p.A., states: "With the signing of these three new agreements PharmaNutra is going to be present in 88 foreign countries, a very remarkable result. These are important figures, achieved in just over ten years of the Group's international activities, thus being even more significant. It is clear that what makes the difference is the scientific value of our products, which comes from the extraordinary work of the Research & Development department. Such a strength makes us look to the present with great satisfaction and to the future with equal optimism".
PharmaNutra S.p.A.
Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process. PharmaNutra is a leader in the production of iron-based nutritional supplements under the SiderAL® brand, where it holds important patents on Sucrosomial® Technology, and is considered one of the emerging top players in the medical device sector dedicated to restoring joint capacity thanks to the Cetilar® brand. The latter is now also on the market in the Nutrition version: a line of food supplements designed for those who practice sport frequently. Over the years, the Group present abroad in 89 countries - has developed a precise strategy in the production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.
For further details:
Via Campodavela, 1 - 56122 Pisa, Italy Tel. +39 050 7846500 [email protected]
Internal Press Office [email protected]
PharmaNutra S.p.A. Press Office - Spriano Communication & Partners
Via Santa Radegonda, 16 - 20121 Milan, Italy Tel. +39 02 83635708
Matteo Russo [email protected] Cristina Tronconi [email protected]
Registered office Via Campodavela, 1 - 56122 Pisa, Italy | +39 050 7846500 pharmanutra.it | [email protected] | [email protected] Tax ID no. / VAT no. / Trade Reg. no. 01679440501 - SDI Code SUBM70N Sh. Cap. 1,123,097.70 € fully paid in | REA Economic and Administrative Index 146259
| Fine Comunicato n.20106-21-2025 | Numero di Pagine: 4 |
|---|---|